AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO

benzinga.com/news/health-care/25/06/45729253/astrazeneca-highlights-significant-gains-across-three-major-cancer-trials-at-asco

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and SERENA-6.
In the DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) combined with…

This story appeared on benzinga.com, 2025-06-02 17:15:59.
The Entire Business World on a Single Page. Free to Use →